[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvsQ1D4-MMFlTM3y3NeICpd6Oay-CKSYtiX9aMt4P8z8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Heidelberg University",[4],285,false,15,23,63621,3,213,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Healthy",12,{"name":18,"count":19},"Pulmonary Hypertension",10,{"name":21,"count":22},"Malaria",6,{"name":24,"count":22},"Depression",{"name":26,"count":27},"COPD",5,{"name":29,"count":27},"Pharmacokinetics",{"name":31,"count":32},"Invasive Aspergillosis",4,{"name":34,"count":32},"Cerebral Palsy",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03925194","A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF","2026-12-01","Anakinra",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05045664","Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody","2027-09-30","Standard",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,80,98,119,161,189,207,234,258,284,310,335,362,380,406,443,468,493,517,546,564,588,619,637,655,684,702,720,738,788,831,858,888,916,934,952,977,995,1021,1045,1063,1081,1107,1136,1161,1187,1205,1231,1256,1274,1292,1316,1340,1365,1389,1416,1438,1456,1477,1501,1532,1554,1580,1603,1628,1652,1673,1696,1720,1742,1790,1826,1848,1876,1900,1926,1944,1971,1989,2007,2028,2053,2077,2095],{"intervention":45,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":76,"NA":78},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":55,"soonestReadout":44},[66],{"nctId":42,"briefTitle":43,"status":67,"phases":68,"primaryCompletion":44,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[50],"2030-06-30","2022-07-06",100,[73],"Early Stage Follicular Lymphoma WHO Grade 1\u002F2 or 3a",[45,75],"Experimental",{"trials":77,"activeCount":59},[],{"trials":79,"activeCount":59},[],{"intervention":75,"totalTrials":55,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":94,"NA":96},{"trials":83,"activeCount":59},[],{"trials":85,"activeCount":59},[],{"trials":87,"activeCount":59},[],{"trials":89,"activeCount":55,"soonestReadout":44},[90],{"nctId":42,"briefTitle":43,"status":67,"phases":91,"primaryCompletion":44,"completion":69,"start":70,"enrollment":71,"conditions":92,"interventions":93},[50],[73],[45,75],{"trials":95,"activeCount":59},[],{"trials":97,"activeCount":59},[],{"intervention":40,"totalTrials":55,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":101,"activeCount":59},[],{"trials":103,"activeCount":59},[],{"trials":105,"activeCount":55,"soonestReadout":39},[106],{"nctId":37,"briefTitle":38,"status":67,"phases":107,"primaryCompletion":39,"completion":39,"start":108,"enrollment":109,"conditions":110,"interventions":112},[49],"2022-12-01",52,[111],"Cystic Fibrosis, 10011762",[40],{"trials":114,"activeCount":59},[],{"trials":116,"activeCount":59},[],{"trials":118,"activeCount":59},[],{"intervention":120,"totalTrials":121,"cells":122},"Riociguat",2,{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":144,"PHASE4":146,"NA":159},{"trials":124,"activeCount":59},[],{"trials":126,"activeCount":59},[],{"trials":128,"activeCount":59},[129],{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":142},"NCT05339087","Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH","TERMINATED",[49],"2025-07-31","2022-10-24",35,[138,139,140,141],"Pulmonary Vascular Disorder","Primary Pulmonary Hypertension","Systemic Sclerosis","Other Systemic Involvement of Connective Tissue",[143],"Riociguat Oral",{"trials":145,"activeCount":59},[],{"trials":147,"activeCount":59},[148],{"nctId":149,"briefTitle":150,"status":132,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":158},"NCT04954742","Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH",[51],"2025-08-13","2022-04-13",30,[156,157],"Primary Pulmonary Arterial Hypertension","Chronic Thromboembolic Pulmonary Hypertension",[120],{"trials":160,"activeCount":59},[],{"intervention":162,"totalTrials":55,"cells":163},"Insulin Glargin",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":187},{"trials":165,"activeCount":59},[],{"trials":167,"activeCount":59},[],{"trials":169,"activeCount":59},[],{"trials":171,"activeCount":59},[],{"trials":173,"activeCount":59},[174],{"nctId":175,"briefTitle":176,"status":177,"phases":178,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},"NCT00523393","Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells","UNKNOWN",[51],"2009-12","2010-05","2007-08",75,[184],"Type 2 Diabetes",[162,186],"Human Insulin",{"trials":188,"activeCount":59},[],{"intervention":186,"totalTrials":55,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":205},{"trials":192,"activeCount":59},[],{"trials":194,"activeCount":59},[],{"trials":196,"activeCount":59},[],{"trials":198,"activeCount":59},[],{"trials":200,"activeCount":59},[201],{"nctId":175,"briefTitle":176,"status":177,"phases":202,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":203,"interventions":204},[51],[184],[162,186],{"trials":206,"activeCount":59},[],{"intervention":208,"totalTrials":55,"cells":209},"viscum album pini",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":232},{"trials":211,"activeCount":59},[],{"trials":213,"activeCount":59},[],{"trials":215,"activeCount":59},[],{"trials":217,"activeCount":59},[],{"trials":219,"activeCount":59},[220],{"nctId":221,"briefTitle":222,"status":223,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT00176046","Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study","COMPLETED",[51],"2009-06","2009-07","1999-05",114,[230],"Metastatic Breast Cancer",[208,208],{"trials":233,"activeCount":59},[],{"intervention":235,"totalTrials":55,"cells":236},"Prothrombin complex concentrate",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":256},{"trials":238,"activeCount":59},[],{"trials":240,"activeCount":59},[],{"trials":242,"activeCount":59},[],{"trials":244,"activeCount":59},[],{"trials":246,"activeCount":59},[247],{"nctId":248,"briefTitle":249,"status":223,"phases":250,"primaryCompletion":251,"completion":251,"start":226,"enrollment":252,"conditions":253,"interventions":255},"NCT00928915","International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage",[51],"2015-01",54,[254],"Intracranial Hemorrhages",[235],{"trials":257,"activeCount":59},[],{"intervention":259,"totalTrials":55,"cells":260},"esomeprazole 20 mg",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":282},{"trials":262,"activeCount":59},[],{"trials":264,"activeCount":59},[],{"trials":266,"activeCount":59},[],{"trials":268,"activeCount":59},[],{"trials":270,"activeCount":59},[271],{"nctId":272,"briefTitle":273,"status":223,"phases":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":281},"NCT00472550","Esomeprazole and Gastric Emptying of Beer",[51],"2006-11","2006-01",16,[279,280],"Gastroesophageal Reflux","Heartburn",[259],{"trials":283,"activeCount":59},[],{"intervention":285,"totalTrials":55,"cells":286},"lactate and bicarbonate buffered dialysis solutions",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":308},{"trials":288,"activeCount":59},[],{"trials":290,"activeCount":59},[],{"trials":292,"activeCount":59},[],{"trials":294,"activeCount":59},[],{"trials":296,"activeCount":59},[297],{"nctId":298,"briefTitle":299,"status":223,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":307},"NCT01632046","Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children",[51],"2007-03","2004-03",42,[305,306],"Chronic Renal Failure","Peritoneal Membrane Disorder",[285],{"trials":309,"activeCount":59},[],{"intervention":311,"totalTrials":55,"cells":312},"two complex naturopathic add-on therapies, leaflet 5-a-day",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":333},{"trials":314,"activeCount":59},[],{"trials":316,"activeCount":59},[],{"trials":318,"activeCount":59},[],{"trials":320,"activeCount":59},[],{"trials":322,"activeCount":59},[323],{"nctId":324,"briefTitle":325,"status":223,"phases":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT00160901","Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer",[51],"2005-12","2003-08",150,[331],"Breast Cancer",[311],{"trials":334,"activeCount":59},[],{"intervention":336,"totalTrials":55,"cells":337},"Cyclosporine discontinuation",{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":360},{"trials":339,"activeCount":59},[],{"trials":341,"activeCount":59},[],{"trials":343,"activeCount":59},[],{"trials":345,"activeCount":59},[],{"trials":347,"activeCount":59},[348],{"nctId":349,"briefTitle":350,"status":223,"phases":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":358},"NCT00123331","Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization\u002FImprovement of Renal Function After Heart Transplantation",[51],"2005-04","2003-10",40,[356,357],"Heart Transplantation","Renal Failure",[336,359],"Rapamycin medication",{"trials":361,"activeCount":59},[],{"intervention":359,"totalTrials":55,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":378},{"trials":365,"activeCount":59},[],{"trials":367,"activeCount":59},[],{"trials":369,"activeCount":59},[],{"trials":371,"activeCount":59},[],{"trials":373,"activeCount":59},[374],{"nctId":349,"briefTitle":350,"status":223,"phases":375,"completion":352,"start":353,"enrollment":354,"conditions":376,"interventions":377},[51],[356,357],[336,359],{"trials":379,"activeCount":59},[],{"intervention":381,"totalTrials":55,"cells":382},"ovaria comp 10 globuli 3 times per day 24 weeks",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":404},{"trials":384,"activeCount":59},[],{"trials":386,"activeCount":59},[],{"trials":388,"activeCount":59},[],{"trials":390,"activeCount":59},[],{"trials":392,"activeCount":59},[393],{"nctId":394,"briefTitle":395,"status":223,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":403},"NCT00152776","Treating Climacteric Symptoms With a Complex Homeopathic Remedy",[51],"2006-12","2005-02",102,[401,402,24],"Menopause","Anxiety Disorders",[381],{"trials":405,"activeCount":59},[],{"intervention":407,"totalTrials":121,"cells":408},"Temozolomide",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":425,"PHASE4":439,"NA":441},{"trials":410,"activeCount":59},[],{"trials":412,"activeCount":59},[],{"trials":414,"activeCount":59},[415],{"nctId":416,"briefTitle":417,"status":177,"phases":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT00311857","Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)",[48,49],"2006-02",46,[422],"Glioblastoma Multiforme",[424,407],"Cetuximab",{"trials":426,"activeCount":59},[427],{"nctId":428,"briefTitle":429,"status":223,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":438},"NCT01502241","Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly",[50],"2010-11","2011-11","2005-01",412,[436,437],"Glioblastoma","Anaplastic Astrocytoma",[407],{"trials":440,"activeCount":59},[],{"trials":442,"activeCount":59},[],{"intervention":444,"totalTrials":55,"cells":445},"Adalimumab",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":464,"NA":466},{"trials":447,"activeCount":59},[],{"trials":449,"activeCount":59},[],{"trials":451,"activeCount":59},[],{"trials":453,"activeCount":59},[454],{"nctId":455,"briefTitle":456,"status":177,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":354,"conditions":461,"interventions":463},"NCT00348153","Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)",[49,50],"2012-09","2013-03","2006-08",[462],"Uveitis",[444],{"trials":465,"activeCount":59},[],{"trials":467,"activeCount":59},[],{"intervention":469,"totalTrials":55,"cells":470},"Emend",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":489,"NA":491},{"trials":472,"activeCount":59},[],{"trials":474,"activeCount":59},[],{"trials":476,"activeCount":59},[],{"trials":478,"activeCount":59},[479],{"nctId":480,"briefTitle":481,"status":177,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":488},"NCT00571168","Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy",[50],"2010-12","2005-07",362,[487],"Multiple Myeloma",[469],{"trials":490,"activeCount":59},[],{"trials":492,"activeCount":59},[],{"intervention":494,"totalTrials":55,"cells":495},"moxifloxacin",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":513,"NA":515},{"trials":497,"activeCount":59},[],{"trials":499,"activeCount":59},[],{"trials":501,"activeCount":59},[],{"trials":503,"activeCount":59},[504],{"nctId":505,"briefTitle":506,"status":223,"phases":507,"primaryCompletion":431,"completion":483,"start":508,"enrollment":509,"conditions":510,"interventions":512},"NCT00447304","Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy",[50],"2006-10",644,[511],"Acute Cholecystitis",[494],{"trials":514,"activeCount":59},[],{"trials":516,"activeCount":59},[],{"intervention":518,"totalTrials":55,"cells":519},"Interferon beta",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":542,"NA":544},{"trials":521,"activeCount":59},[],{"trials":523,"activeCount":59},[],{"trials":525,"activeCount":59},[],{"trials":527,"activeCount":59},[528],{"nctId":529,"briefTitle":530,"status":223,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":540},"NCT00344253","Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis",[50],"2011-03","2012-01","2006-03",19,[537,538,539],"Uveitis, Intermediate","Macular Edema","Multiple Sclerosis",[518,541],"Methotrexate",{"trials":543,"activeCount":59},[],{"trials":545,"activeCount":59},[],{"intervention":541,"totalTrials":55,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":560,"NA":562},{"trials":549,"activeCount":59},[],{"trials":551,"activeCount":59},[],{"trials":553,"activeCount":59},[],{"trials":555,"activeCount":59},[556],{"nctId":529,"briefTitle":530,"status":223,"phases":557,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":558,"interventions":559},[50],[537,538,539],[518,541],{"trials":561,"activeCount":59},[],{"trials":563,"activeCount":59},[],{"intervention":565,"totalTrials":55,"cells":566},"Ancrod",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":584,"NA":586},{"trials":568,"activeCount":59},[],{"trials":570,"activeCount":59},[],{"trials":572,"activeCount":59},[],{"trials":574,"activeCount":59},[575],{"nctId":576,"briefTitle":577,"status":223,"phases":578,"conditions":579,"interventions":583},"NCT00343174","Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms",[50],[580,581,582],"Brain Infarction","Cerebral Ischemia","Acute Stroke",[565],{"trials":585,"activeCount":59},[],{"trials":587,"activeCount":59},[],{"intervention":589,"totalTrials":55,"cells":590},"ACE Inhibition",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":615,"NA":617},{"trials":592,"activeCount":59},[],{"trials":594,"activeCount":59},[],{"trials":596,"activeCount":59},[],{"trials":598,"activeCount":59},[599],{"nctId":600,"briefTitle":601,"status":223,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":612},"NCT00221845","Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients",[50],"2007-07","2010-01","1998-01",400,[608,305,609,610,611],"Children","Hypertension","Acquired Kidney Disease","Congenital Kidney Disease",[589,613,614],"Intensified Blood Pressure Control","Add-on Angiotensin Receptor Blockade",{"trials":616,"activeCount":59},[],{"trials":618,"activeCount":59},[],{"intervention":613,"totalTrials":55,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":633,"NA":635},{"trials":622,"activeCount":59},[],{"trials":624,"activeCount":59},[],{"trials":626,"activeCount":59},[],{"trials":628,"activeCount":59},[629],{"nctId":600,"briefTitle":601,"status":223,"phases":630,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":631,"interventions":632},[50],[608,305,609,610,611],[589,613,614],{"trials":634,"activeCount":59},[],{"trials":636,"activeCount":59},[],{"intervention":614,"totalTrials":55,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":651,"NA":653},{"trials":640,"activeCount":59},[],{"trials":642,"activeCount":59},[],{"trials":644,"activeCount":59},[],{"trials":646,"activeCount":59},[647],{"nctId":600,"briefTitle":601,"status":223,"phases":648,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":649,"interventions":650},[50],[608,305,609,610,611],[589,613,614],{"trials":652,"activeCount":59},[],{"trials":654,"activeCount":59},[],{"intervention":656,"totalTrials":55,"cells":657},"recombinant interferon alfa",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":680,"NA":682},{"trials":659,"activeCount":59},[],{"trials":661,"activeCount":59},[],{"trials":663,"activeCount":59},[],{"trials":665,"activeCount":59},[666],{"nctId":667,"briefTitle":668,"status":223,"phases":669,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":676},"NCT00055874","Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",[50],"2012-03-31","2017-03-31","2002-06",1551,[675],"Leukemia",[656,677,678,679],"cytarabine","hydroxyurea","imatinib mesylate",{"trials":681,"activeCount":59},[],{"trials":683,"activeCount":59},[],{"intervention":677,"totalTrials":55,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":698,"NA":700},{"trials":687,"activeCount":59},[],{"trials":689,"activeCount":59},[],{"trials":691,"activeCount":59},[],{"trials":693,"activeCount":59},[694],{"nctId":667,"briefTitle":668,"status":223,"phases":695,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":696,"interventions":697},[50],[675],[656,677,678,679],{"trials":699,"activeCount":59},[],{"trials":701,"activeCount":59},[],{"intervention":678,"totalTrials":55,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":716,"NA":718},{"trials":705,"activeCount":59},[],{"trials":707,"activeCount":59},[],{"trials":709,"activeCount":59},[],{"trials":711,"activeCount":59},[712],{"nctId":667,"briefTitle":668,"status":223,"phases":713,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":714,"interventions":715},[50],[675],[656,677,678,679],{"trials":717,"activeCount":59},[],{"trials":719,"activeCount":59},[],{"intervention":679,"totalTrials":55,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":734,"NA":736},{"trials":723,"activeCount":59},[],{"trials":725,"activeCount":59},[],{"trials":727,"activeCount":59},[],{"trials":729,"activeCount":59},[730],{"nctId":667,"briefTitle":668,"status":223,"phases":731,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":732,"interventions":733},[50],[675],[656,677,678,679],{"trials":735,"activeCount":59},[],{"trials":737,"activeCount":59},[],{"intervention":424,"totalTrials":32,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":782,"PHASE4":784,"NA":786},{"trials":741,"activeCount":59},[],{"trials":743,"activeCount":59},[],{"trials":745,"activeCount":59},[746,757,769,778],{"nctId":747,"briefTitle":748,"status":177,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":756},"NCT01192087","Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy",[48,49],"2015-07","2017-07","2012-06",49,[755],"Adenoid Cystic Carcinoma",[424],{"nctId":758,"briefTitle":759,"status":177,"phases":760,"primaryCompletion":761,"completion":762,"start":226,"enrollment":329,"conditions":763,"interventions":766},"NCT00894569","Paclitaxel\u002FCarboplatin With or Without Cetuximab in CUP",[49],"2010-07","2011-08",[764,765],"Neoplasms, Unknown Primary","Carcinoma",[767,768],"paclitaxel\u002Fcarboplatin","cetuximab",{"nctId":770,"briefTitle":771,"status":223,"phases":772,"primaryCompletion":225,"completion":773,"start":774,"enrollment":154,"conditions":775,"interventions":777},"NCT00115518","Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",[49],"2010-08","2005-05",[776],"Carcinoma, Non-Small-Cell Lung",[768],{"nctId":416,"briefTitle":417,"status":177,"phases":779,"start":419,"enrollment":420,"conditions":780,"interventions":781},[48,49],[422],[424,407],{"trials":783,"activeCount":59},[],{"trials":785,"activeCount":59},[],{"trials":787,"activeCount":59},[],{"intervention":789,"totalTrials":11,"cells":790},"artesunate",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":804,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":792,"activeCount":59},[],{"trials":794,"activeCount":59},[795],{"nctId":796,"briefTitle":797,"status":223,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":9,"conditions":801,"interventions":803},"NCT00764036","Study of Artesunate in Metastatic Breast Cancer",[48],"2013-11","2008-10",[230,802],"Locally Advanced Breast Cancer",[789],{"trials":805,"activeCount":59},[806,815],{"nctId":807,"briefTitle":808,"status":223,"phases":809,"primaryCompletion":762,"completion":810,"start":762,"enrollment":811,"conditions":812,"interventions":814},"NCT01407887","Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children",[49],"2011-12",180,[813],"Uncomplicated Falciparum Malaria",[789],{"nctId":816,"briefTitle":817,"status":223,"phases":818,"completion":275,"start":819,"conditions":820,"interventions":821},"NCT00354380","Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study",[49],"2006-09",[21],[822,823,824],"Methylene blue","Artesunate","Amodiaquine",{"trials":826,"activeCount":59},[],{"trials":828,"activeCount":59},[],{"trials":830,"activeCount":59},[],{"intervention":824,"totalTrials":121,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":834,"activeCount":59},[],{"trials":836,"activeCount":59},[],{"trials":838,"activeCount":59},[839,848],{"nctId":840,"briefTitle":841,"status":223,"phases":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":847},"NCT00261222","Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso",[49],"2005-11","2005-09",120,[21],[824],{"nctId":816,"briefTitle":817,"status":223,"phases":849,"completion":275,"start":819,"conditions":850,"interventions":851},[49],[21],[822,823,824],{"trials":853,"activeCount":59},[],{"trials":855,"activeCount":59},[],{"trials":857,"activeCount":59},[],{"intervention":822,"totalTrials":121,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":861,"activeCount":59},[],{"trials":863,"activeCount":59},[],{"trials":865,"activeCount":59},[866,870],{"nctId":816,"briefTitle":817,"status":223,"phases":867,"completion":275,"start":819,"conditions":868,"interventions":869},[49],[21],[822,823,824],{"nctId":871,"briefTitle":872,"status":223,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":71,"conditions":877,"interventions":879},"NCT02851108","Methylene Blue Against Falciparum Malaria in Burkina Faso",[49],"2016-12","2017-02","2016-10",[878],"Malaria, Falciparum",[880,881],"Methylene Blue","Primaquine",{"trials":883,"activeCount":59},[],{"trials":885,"activeCount":59},[],{"trials":887,"activeCount":59},[],{"intervention":889,"totalTrials":55,"cells":890},"Artemeter-Lumefantrine and MB",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":892,"activeCount":59},[],{"trials":894,"activeCount":59},[],{"trials":896,"activeCount":59},[897],{"nctId":898,"briefTitle":899,"status":900,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":59,"conditions":905,"interventions":907},"NCT02696928","Methylene Blue Against Vivax Malaria in Ethiopia","WITHDRAWN",[49],"2017-10","2018-01","2016-04",[906],"Vivax Malaria",[889,908,909],"Artemeter-Lumefantrine","Artemeter-Lumefantrine and Primaquine",{"trials":911,"activeCount":59},[],{"trials":913,"activeCount":59},[],{"trials":915,"activeCount":59},[],{"intervention":908,"totalTrials":55,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":919,"activeCount":59},[],{"trials":921,"activeCount":59},[],{"trials":923,"activeCount":59},[924],{"nctId":898,"briefTitle":899,"status":900,"phases":925,"primaryCompletion":902,"completion":903,"start":904,"enrollment":59,"conditions":926,"interventions":927},[49],[906],[889,908,909],{"trials":929,"activeCount":59},[],{"trials":931,"activeCount":59},[],{"trials":933,"activeCount":59},[],{"intervention":909,"totalTrials":55,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":937,"activeCount":59},[],{"trials":939,"activeCount":59},[],{"trials":941,"activeCount":59},[942],{"nctId":898,"briefTitle":899,"status":900,"phases":943,"primaryCompletion":902,"completion":903,"start":904,"enrollment":59,"conditions":944,"interventions":945},[49],[906],[889,908,909],{"trials":947,"activeCount":59},[],{"trials":949,"activeCount":59},[],{"trials":951,"activeCount":59},[],{"intervention":953,"totalTrials":55,"cells":954},"Vasopressors to maintain normal blood pressure values, if needed",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":956,"activeCount":59},[],{"trials":958,"activeCount":59},[],{"trials":960,"activeCount":59},[961],{"nctId":962,"briefTitle":963,"status":177,"phases":964,"primaryCompletion":903,"completion":965,"start":966,"enrollment":71,"conditions":967,"interventions":969},"NCT02317497","Sedation Depth in Neurocritical Care",[49],"2018-11","2016-09",[968],"Sedation of Cerebrovascular Ventilated Critical Care Patients",[953,970],"Osmotherapeutics to lowr intracranial pressure, if needed",{"trials":972,"activeCount":59},[],{"trials":974,"activeCount":59},[],{"trials":976,"activeCount":59},[],{"intervention":970,"totalTrials":55,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":980,"activeCount":59},[],{"trials":982,"activeCount":59},[],{"trials":984,"activeCount":59},[985],{"nctId":962,"briefTitle":963,"status":177,"phases":986,"primaryCompletion":903,"completion":965,"start":966,"enrollment":71,"conditions":987,"interventions":988},[49],[968],[953,970],{"trials":990,"activeCount":59},[],{"trials":992,"activeCount":59},[],{"trials":994,"activeCount":59},[],{"intervention":996,"totalTrials":55,"cells":997},"Cyclophosphamide, Pentostatin, Rituximab",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":999,"activeCount":59},[],{"trials":1001,"activeCount":59},[],{"trials":1003,"activeCount":59},[1004],{"nctId":1005,"briefTitle":1006,"status":177,"phases":1007,"primaryCompletion":1008,"completion":533,"start":398,"enrollment":1009,"conditions":1010,"interventions":1014},"NCT00927797","Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)",[49],"2009-01",185,[1011,1012,1013],"Immunocytoma\u002FMorbus Waldenström","B-Cell Non-Hodgkin's Lymphoma","B-Cell Chronic Lymphocytic Leukemia",[996],{"trials":1016,"activeCount":59},[],{"trials":1018,"activeCount":59},[],{"trials":1020,"activeCount":59},[],{"intervention":1022,"totalTrials":55,"cells":1023},"6% Hypertonic Saline (HS), 4mL",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1025,"activeCount":59},[],{"trials":1027,"activeCount":59},[],{"trials":1029,"activeCount":59},[1030],{"nctId":1031,"briefTitle":1032,"status":223,"phases":1033,"primaryCompletion":1034,"completion":902,"start":752,"enrollment":303,"conditions":1035,"interventions":1037},"NCT01619657","Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis",[49],"2016-11",[1036],"Cystic Fibrosis Lung Disease",[1022,1038],"0.9% Isotonic Saline (IS), 4mL",{"trials":1040,"activeCount":59},[],{"trials":1042,"activeCount":59},[],{"trials":1044,"activeCount":59},[],{"intervention":1038,"totalTrials":55,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1057,"PHASE4":1059,"NA":1061},{"trials":1048,"activeCount":59},[],{"trials":1050,"activeCount":59},[],{"trials":1052,"activeCount":59},[1053],{"nctId":1031,"briefTitle":1032,"status":223,"phases":1054,"primaryCompletion":1034,"completion":902,"start":752,"enrollment":303,"conditions":1055,"interventions":1056},[49],[1036],[1022,1038],{"trials":1058,"activeCount":59},[],{"trials":1060,"activeCount":59},[],{"trials":1062,"activeCount":59},[],{"intervention":767,"totalTrials":55,"cells":1064},{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1066,"activeCount":59},[],{"trials":1068,"activeCount":59},[],{"trials":1070,"activeCount":59},[1071],{"nctId":758,"briefTitle":759,"status":177,"phases":1072,"primaryCompletion":761,"completion":762,"start":226,"enrollment":329,"conditions":1073,"interventions":1074},[49],[764,765],[767,768],{"trials":1076,"activeCount":59},[],{"trials":1078,"activeCount":59},[],{"trials":1080,"activeCount":59},[],{"intervention":1082,"totalTrials":55,"cells":1083},"EIA chemotherapy",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1085,"activeCount":59},[],{"trials":1087,"activeCount":59},[],{"trials":1089,"activeCount":59},[1090],{"nctId":1091,"briefTitle":1092,"status":223,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT01382030","Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma",[49],"2010-09","2011-01","2005-06",50,[1099],"Soft Tissue Sarcoma",[1082],{"trials":1102,"activeCount":59},[],{"trials":1104,"activeCount":59},[],{"trials":1106,"activeCount":59},[],{"intervention":1108,"totalTrials":55,"cells":1109},"Obinutuzumab Injection [Gazyva]",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1111,"activeCount":59},[],{"trials":1113,"activeCount":59},[],{"trials":1115,"activeCount":59},[1116],{"nctId":1117,"briefTitle":1118,"status":223,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1129},"NCT03341520","Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma",[49],"2021-11-11","2024-03-14","2018-04-24",89,[1125,1126,1127,1128],"Stage II Grade 1 Follicular Lymphoma","Stage II Grade 2 Follicular Lymphoma","Stage I Follicular Lymphoma Grade 1","Stage II Follicular Lymphoma Grade 2",[1108],{"trials":1131,"activeCount":59},[],{"trials":1133,"activeCount":59},[],{"trials":1135,"activeCount":59},[],{"intervention":1137,"totalTrials":55,"cells":1138},"Imatinib",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1140,"activeCount":59},[],{"trials":1142,"activeCount":59},[],{"trials":1144,"activeCount":59},[1145],{"nctId":1146,"briefTitle":1147,"status":223,"phases":1148,"primaryCompletion":874,"completion":874,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1154},"NCT01137916","Study to Evaluate Imatinib in Desmoid Tumors",[49],"2010-06",39,[1152,1153],"Aggressive Fibromatosis","Desmoid Tumor",[1137],{"trials":1156,"activeCount":59},[],{"trials":1158,"activeCount":59},[],{"trials":1160,"activeCount":59},[],{"intervention":1162,"totalTrials":55,"cells":1163},"Immunochemotherapy",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1165,"activeCount":59},[],{"trials":1167,"activeCount":59},[],{"trials":1169,"activeCount":59},[1170],{"nctId":1171,"briefTitle":1172,"status":177,"phases":1173,"primaryCompletion":483,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT00946374","Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma",[49],"2011-06","2004-07",20,[1178],"Mantle-Cell Lymphoma",[1162,1180],"High-dose BEAM plus autologous SCT",{"trials":1182,"activeCount":59},[],{"trials":1184,"activeCount":59},[],{"trials":1186,"activeCount":59},[],{"intervention":1180,"totalTrials":55,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1190,"activeCount":59},[],{"trials":1192,"activeCount":59},[],{"trials":1194,"activeCount":59},[1195],{"nctId":1171,"briefTitle":1172,"status":177,"phases":1196,"primaryCompletion":483,"completion":1174,"start":1175,"enrollment":1176,"conditions":1197,"interventions":1198},[49],[1178],[1162,1180],{"trials":1200,"activeCount":59},[],{"trials":1202,"activeCount":59},[],{"trials":1204,"activeCount":59},[],{"intervention":1206,"totalTrials":55,"cells":1207},"Pazopanib + Paclitaxel",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1209,"activeCount":59},[],{"trials":1211,"activeCount":59},[],{"trials":1213,"activeCount":59},[1214],{"nctId":1215,"briefTitle":1216,"status":132,"phases":1217,"primaryCompletion":1218,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT02212015","Evaluation of Votrient in Angiosarcoma",[49],"2019-12-31","2020-07-01","2014-07",26,[1223],"Angiosarcoma",[1206],{"trials":1226,"activeCount":59},[],{"trials":1228,"activeCount":59},[],{"trials":1230,"activeCount":59},[],{"intervention":1232,"totalTrials":55,"cells":1233},"Methylenblue-Amodiaquine",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1235,"activeCount":59},[],{"trials":1237,"activeCount":59},[],{"trials":1239,"activeCount":59},[1240],{"nctId":1241,"briefTitle":1242,"status":223,"phases":1243,"completion":1244,"start":603,"enrollment":1245,"conditions":1246,"interventions":1247},"NCT00545935","Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso",[49],"2007-10",186,[21],[1232,1248,1249],"Methylenblue-Artesunate","Artesunate-Amodiaquine",{"trials":1251,"activeCount":59},[],{"trials":1253,"activeCount":59},[],{"trials":1255,"activeCount":59},[],{"intervention":1248,"totalTrials":55,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1259,"activeCount":59},[],{"trials":1261,"activeCount":59},[],{"trials":1263,"activeCount":59},[1264],{"nctId":1241,"briefTitle":1242,"status":223,"phases":1265,"completion":1244,"start":603,"enrollment":1245,"conditions":1266,"interventions":1267},[49],[21],[1232,1248,1249],{"trials":1269,"activeCount":59},[],{"trials":1271,"activeCount":59},[],{"trials":1273,"activeCount":59},[],{"intervention":1249,"totalTrials":55,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1277,"activeCount":59},[],{"trials":1279,"activeCount":59},[],{"trials":1281,"activeCount":59},[1282],{"nctId":1241,"briefTitle":1242,"status":223,"phases":1283,"completion":1244,"start":603,"enrollment":1245,"conditions":1284,"interventions":1285},[49],[21],[1232,1248,1249],{"trials":1287,"activeCount":59},[],{"trials":1289,"activeCount":59},[],{"trials":1291,"activeCount":59},[],{"intervention":1293,"totalTrials":55,"cells":1294},"Lenalidomide",{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1296,"activeCount":59},[],{"trials":1298,"activeCount":59},[],{"trials":1300,"activeCount":59},[1301],{"nctId":1302,"briefTitle":1303,"status":223,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1097,"conditions":1307,"interventions":1309},"NCT00883623","A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis",[49],"2013-02","2009-04",[1308],"Primary Amyloidosis",[1293],{"trials":1311,"activeCount":59},[],{"trials":1313,"activeCount":59},[],{"trials":1315,"activeCount":59},[],{"intervention":1317,"totalTrials":55,"cells":1318},"Chlorhexidine solution 4%",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1334,"PHASE4":1336,"NA":1338},{"trials":1320,"activeCount":59},[],{"trials":1322,"activeCount":59},[],{"trials":1324,"activeCount":59},[1325],{"nctId":1326,"briefTitle":1327,"status":223,"phases":1328,"completion":1329,"start":1330,"enrollment":71,"conditions":1331,"interventions":1333},"NCT00266448","Whole Body Washing With Chlorhexidine for the Eradication of MRSA",[49],"2004-04","2001-01",[1332],"MRSA-Colonization",[1317],{"trials":1335,"activeCount":59},[],{"trials":1337,"activeCount":59},[],{"trials":1339,"activeCount":59},[],{"intervention":1341,"totalTrials":55,"cells":1342},"Ambrisentan",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1344,"activeCount":59},[],{"trials":1346,"activeCount":59},[],{"trials":1348,"activeCount":59},[1349],{"nctId":1350,"briefTitle":1351,"status":223,"phases":1352,"primaryCompletion":1353,"completion":1354,"start":1355,"enrollment":1356,"conditions":1357,"interventions":1358},"NCT02290613","Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)",[49],"2017-11-27","2017-12-31","2014-07-01",38,[140,18],[1341],{"trials":1360,"activeCount":59},[],{"trials":1362,"activeCount":59},[],{"trials":1364,"activeCount":59},[],{"intervention":1366,"totalTrials":55,"cells":1367},"Inhaled Iloprost",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1383,"PHASE4":1385,"NA":1387},{"trials":1369,"activeCount":59},[],{"trials":1371,"activeCount":59},[],{"trials":1373,"activeCount":59},[1374],{"nctId":1375,"briefTitle":1376,"status":900,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":59,"conditions":1380,"interventions":1382},"NCT02482402","Iloprost for Bridging to Heart Transplantation in PH",[49],"2015-03-17","2015-02",[1381,18],"Chronic Left Ventricular Failure",[1366],{"trials":1384,"activeCount":59},[],{"trials":1386,"activeCount":59},[],{"trials":1388,"activeCount":59},[],{"intervention":1390,"totalTrials":55,"cells":1391},"Oxygen",{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1393,"activeCount":59},[],{"trials":1395,"activeCount":59},[],{"trials":1397,"activeCount":59},[1398],{"nctId":1399,"briefTitle":1400,"status":223,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1176,"conditions":1405,"interventions":1409},"NCT04207593","The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia",[49],"2023-01-01","2023-01-10","2019-04-01",[1406,1407,1408],"Oxygen Deficiency","Pulmonary Arterial Hypertension","CTEPH",[1390],{"trials":1411,"activeCount":59},[],{"trials":1413,"activeCount":59},[],{"trials":1415,"activeCount":59},[],{"intervention":1417,"totalTrials":55,"cells":1418},"Vorinostat",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1420,"activeCount":59},[],{"trials":1422,"activeCount":59},[],{"trials":1424,"activeCount":59},[1425],{"nctId":1426,"briefTitle":1427,"status":223,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":180,"enrollment":354,"conditions":1430,"interventions":1431},"NCT00918489","Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)",[49],"2013-09",[1099],[1417],{"trials":1433,"activeCount":59},[],{"trials":1435,"activeCount":59},[],{"trials":1437,"activeCount":59},[],{"intervention":881,"totalTrials":55,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1441,"activeCount":59},[],{"trials":1443,"activeCount":59},[],{"trials":1445,"activeCount":59},[1446],{"nctId":871,"briefTitle":872,"status":223,"phases":1447,"primaryCompletion":874,"completion":875,"start":876,"enrollment":71,"conditions":1448,"interventions":1449},[49],[878],[880,881],{"trials":1451,"activeCount":59},[],{"trials":1453,"activeCount":59},[],{"trials":1455,"activeCount":59},[],{"intervention":1457,"totalTrials":55,"cells":1458},"Methylenblue",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1460,"activeCount":59},[],{"trials":1462,"activeCount":59},[],{"trials":1464,"activeCount":59},[1465],{"nctId":1466,"briefTitle":1467,"status":223,"phases":1468,"conditions":1469,"interventions":1470},"NCT00917202","Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8 Project of the SFB 544",[49],[21],[1457],{"trials":1472,"activeCount":59},[],{"trials":1474,"activeCount":59},[],{"trials":1476,"activeCount":59},[],{"intervention":1478,"totalTrials":55,"cells":1479},"pazopanib",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1481,"activeCount":59},[],{"trials":1483,"activeCount":59},[],{"trials":1485,"activeCount":59},[1486],{"nctId":1487,"briefTitle":1488,"status":132,"phases":1489,"primaryCompletion":876,"completion":876,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1494},"NCT01543802","Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma",[49],"2013-04",21,[1493],"Sarcoma, Soft-tissue",[1478],{"trials":1496,"activeCount":59},[],{"trials":1498,"activeCount":59},[],{"trials":1500,"activeCount":59},[],{"intervention":1502,"totalTrials":121,"cells":1503},"levothyroxine",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1505,"activeCount":59},[],{"trials":1507,"activeCount":59},[1508,1517],{"nctId":1509,"briefTitle":1510,"status":223,"phases":1511,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1516},"NCT01465646","Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine\u002F75 μg Iodine, and 100 μg Levothyroxine\u002F75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 100 μg\u002F 75 μg Tablets",[48],"2003-12","2003-06",24,[29],[1502,1502],{"nctId":1518,"briefTitle":1519,"status":223,"phases":1520,"primaryCompletion":1521,"completion":1521,"start":328,"enrollment":1514,"conditions":1522,"interventions":1523},"NCT01465633","Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine\u002F75 μg Iodine, and 100 μg Levothyroxine\u002F75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg\u002F 75 μg Tablets",[48],"2003-11",[29],[1502,1502],{"trials":1525,"activeCount":59},[],{"trials":1527,"activeCount":59},[],{"trials":1529,"activeCount":59},[],{"trials":1531,"activeCount":59},[],{"intervention":1533,"totalTrials":55,"cells":1534},"sodium nitroprusside, bradykinin, acetylcholine",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1546,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1536,"activeCount":59},[],{"trials":1538,"activeCount":59},[1539],{"nctId":1540,"briefTitle":1541,"status":177,"phases":1542,"completion":397,"start":1543,"enrollment":71,"conditions":1544,"interventions":1545},"NCT00160888","Vasoreactivity in Carriers of Genetic Polymorphisms",[48],"1999-11",[15],[1533],{"trials":1547,"activeCount":59},[],{"trials":1549,"activeCount":59},[],{"trials":1551,"activeCount":59},[],{"trials":1553,"activeCount":59},[],{"intervention":1555,"totalTrials":55,"cells":1556},"Intravitreal",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1558,"activeCount":59},[],{"trials":1560,"activeCount":59},[1561],{"nctId":1562,"briefTitle":1563,"status":177,"phases":1564,"completion":1565,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1571},"NCT00476918","Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema",[48],"2007-12","2006-07",60,[1569,1570],"Diabetic Retinopathy","Diabetic Macular Edema",[1555],{"trials":1573,"activeCount":59},[],{"trials":1575,"activeCount":59},[],{"trials":1577,"activeCount":59},[],{"trials":1579,"activeCount":59},[],{"intervention":1581,"totalTrials":55,"cells":1582},"Nicotinic Acids",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1584,"activeCount":59},[],{"trials":1586,"activeCount":59},[1587],{"nctId":1588,"briefTitle":1589,"status":223,"phases":1590,"primaryCompletion":843,"completion":327,"start":774,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT01258491","Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects",[48],18,[1593],"Healthy Subjects",[1581],{"trials":1596,"activeCount":59},[],{"trials":1598,"activeCount":59},[],{"trials":1600,"activeCount":59},[],{"trials":1602,"activeCount":59},[],{"intervention":1604,"totalTrials":55,"cells":1605},"Mitomycin C-induced peripheral blood mononuclear cells",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1607,"activeCount":59},[],{"trials":1609,"activeCount":59},[1610],{"nctId":1611,"briefTitle":1612,"status":223,"phases":1613,"primaryCompletion":1614,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1619},"NCT02560220","MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients",[48],"2017-04-18","2015-08-05",14,[1618],"Kidney Failure, Chronic",[1604],{"trials":1621,"activeCount":59},[],{"trials":1623,"activeCount":59},[],{"trials":1625,"activeCount":59},[],{"trials":1627,"activeCount":59},[],{"intervention":1629,"totalTrials":55,"cells":1630},"Sunitinib",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1632,"activeCount":59},[],{"trials":1634,"activeCount":59},[1635],{"nctId":1636,"briefTitle":1637,"status":223,"phases":1638,"primaryCompletion":1639,"completion":1379,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1643},"NCT01498835","Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma",[48],"2014-11","2012-02",9,[1099],[1629],{"trials":1645,"activeCount":59},[],{"trials":1647,"activeCount":59},[],{"trials":1649,"activeCount":59},[],{"trials":1651,"activeCount":59},[],{"intervention":1653,"totalTrials":55,"cells":1654},"nicotinic acid",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1656,"activeCount":59},[],{"trials":1658,"activeCount":59},[1659],{"nctId":1660,"briefTitle":1661,"status":177,"phases":1662,"enrollment":1591,"conditions":1663,"interventions":1664},"NCT00176020","Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression",[48],[15],[1653],{"trials":1666,"activeCount":59},[],{"trials":1668,"activeCount":59},[],{"trials":1670,"activeCount":59},[],{"trials":1672,"activeCount":59},[],{"intervention":1674,"totalTrials":55,"cells":1675},"sildenafil, fluvoxamine",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1688,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1677,"activeCount":59},[],{"trials":1679,"activeCount":59},[1680],{"nctId":1681,"briefTitle":1682,"status":223,"phases":1683,"completion":1684,"start":1685,"enrollment":16,"conditions":1686,"interventions":1687},"NCT00175981","Interaction Between Fluvoxamine and Sildenafil",[48],"2004-11","2003-02",[15],[1674],{"trials":1689,"activeCount":59},[],{"trials":1691,"activeCount":59},[],{"trials":1693,"activeCount":59},[],{"trials":1695,"activeCount":59},[],{"intervention":1697,"totalTrials":55,"cells":1698},"Gemcitabine + Trabectedin",{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1712,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1700,"activeCount":59},[],{"trials":1702,"activeCount":59},[1703],{"nctId":1704,"briefTitle":1705,"status":223,"phases":1706,"primaryCompletion":1707,"completion":1707,"start":432,"enrollment":27,"conditions":1708,"interventions":1711},"NCT01426633","Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas",[48],"2014-12",[1709,1710],"Leiomyosarcoma","Liposarcoma",[1697],{"trials":1713,"activeCount":59},[],{"trials":1715,"activeCount":59},[],{"trials":1717,"activeCount":59},[],{"trials":1719,"activeCount":59},[],{"intervention":1721,"totalTrials":55,"cells":1722},"SLV317",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1724,"activeCount":59},[],{"trials":1726,"activeCount":59},[1727],{"nctId":1728,"briefTitle":1729,"status":223,"phases":1730,"completion":1521,"start":1731,"enrollment":1591,"conditions":1732,"interventions":1733},"NCT00160862","NK-1 Antagonism of SLV317 in Humans",[48],"2003-05",[15],[1721],{"trials":1735,"activeCount":59},[],{"trials":1737,"activeCount":59},[],{"trials":1739,"activeCount":59},[],{"trials":1741,"activeCount":59},[],{"intervention":1743,"totalTrials":32,"cells":1744},"retarded release phosphatidylcholine",{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1767,"PHASE4":1776,"NA":1778},{"trials":1746,"activeCount":59},[],{"trials":1748,"activeCount":59},[],{"trials":1750,"activeCount":59},[1751,1759],{"nctId":1752,"briefTitle":1753,"status":223,"phases":1754,"completion":534,"start":1755,"enrollment":1567,"conditions":1756,"interventions":1758},"NCT00259558","Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis",[49],"2003-04",[1757],"Ulcerative Colitis",[1743],{"nctId":1760,"briefTitle":1761,"status":223,"phases":1762,"completion":419,"start":1685,"enrollment":1567,"conditions":1763,"interventions":1765},"NCT00259545","Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis",[49],[1757,1764],"Phosphatidylcholine",[1766],"Retarded Release Phosphatidylcholine",{"trials":1768,"activeCount":59},[1769],{"nctId":1770,"briefTitle":1771,"status":900,"phases":1772,"completion":1773,"enrollment":59,"conditions":1774,"interventions":1775},"NCT00259571","Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.",[49,50],"2010-03",[1757],[1743],{"trials":1777,"activeCount":59},[],{"trials":1779,"activeCount":59},[1780],{"nctId":1781,"briefTitle":1782,"status":223,"phases":1783,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":1787,"interventions":1788},"NCT00463619","Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis",[],"2010-04","2000-04",132,[1757],[1789],"Retarded release phosphatidylcholine",{"intervention":1791,"totalTrials":121,"cells":1792},"Etomidate",{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1794,"activeCount":59},[],{"trials":1796,"activeCount":59},[],{"trials":1798,"activeCount":59},[],{"trials":1800,"activeCount":59},[],{"trials":1802,"activeCount":59},[],{"trials":1804,"activeCount":59},[1805,1816],{"nctId":1806,"briefTitle":1807,"status":177,"phases":1808,"primaryCompletion":1809,"completion":1809,"start":1810,"enrollment":1097,"conditions":1811,"interventions":1813},"NCT04934410","Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation",[],"2022-12-31","2021-11-01",[1812],"Blood Pressure, Low",[1791,1814,1815],"Midazolam","Sevoflurane",{"nctId":1817,"briefTitle":1818,"status":223,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1404,"enrollment":1821,"conditions":1822,"interventions":1825},"NCT04865614","Comparison Between Inhalation and Intravenous Induction of Anaesthesia During Interventional Mitral Valve Repair",[],"2020-12-01",57,[1823,1824],"Blood Pressure","Hypotension Drug-Induced",[1791,1815],{"intervention":1815,"totalTrials":121,"cells":1827},{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1829,"activeCount":59},[],{"trials":1831,"activeCount":59},[],{"trials":1833,"activeCount":59},[],{"trials":1835,"activeCount":59},[],{"trials":1837,"activeCount":59},[],{"trials":1839,"activeCount":59},[1840,1844],{"nctId":1806,"briefTitle":1807,"status":177,"phases":1841,"primaryCompletion":1809,"completion":1809,"start":1810,"enrollment":1097,"conditions":1842,"interventions":1843},[],[1812],[1791,1814,1815],{"nctId":1817,"briefTitle":1818,"status":223,"phases":1845,"primaryCompletion":1820,"completion":1820,"start":1404,"enrollment":1821,"conditions":1846,"interventions":1847},[],[1823,1824],[1791,1815],{"intervention":1849,"totalTrials":55,"cells":1850},"propofol and sevoflurane",{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1852,"activeCount":59},[],{"trials":1854,"activeCount":59},[],{"trials":1856,"activeCount":59},[],{"trials":1858,"activeCount":59},[],{"trials":1860,"activeCount":59},[],{"trials":1862,"activeCount":59},[1863],{"nctId":1864,"briefTitle":1865,"status":223,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1875},"NCT02382445","Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction",[52],"2017-05-08","2014-01",138,[1871,1872,1873,1874],"Anesthesia","Delirium","Dementia","Bispectral Index Monitor",[1849],{"intervention":1877,"totalTrials":55,"cells":1878},"Sunitinib, Pazopanib, Bevacizumab, Everolimus...",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1880,"activeCount":59},[],{"trials":1882,"activeCount":59},[],{"trials":1884,"activeCount":59},[],{"trials":1886,"activeCount":59},[],{"trials":1888,"activeCount":59},[],{"trials":1890,"activeCount":59},[1891],{"nctId":1892,"briefTitle":1893,"status":177,"phases":1894,"primaryCompletion":1895,"completion":1895,"start":1896,"enrollment":32,"conditions":1897,"interventions":1899},"NCT02208128","Molecular Determinants for Therapy Response on Renal Cell Carcinoma",[52],"2018-02","2014-05",[1898],"Renal Cell Carcinoma",[1877],{"intervention":1901,"totalTrials":55,"cells":1902},"High dose propofol, fentanyl and sevoflurane",{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1904,"activeCount":59},[],{"trials":1906,"activeCount":59},[],{"trials":1908,"activeCount":59},[],{"trials":1910,"activeCount":59},[],{"trials":1912,"activeCount":59},[],{"trials":1914,"activeCount":59},[1915],{"nctId":1916,"briefTitle":1917,"status":223,"phases":1918,"primaryCompletion":1919,"completion":459,"start":1920,"enrollment":277,"conditions":1921,"interventions":1924},"NCT02794896","Anesthetic Depth Effects Upon Immune Competent Cells",[52],"2012-03","2009-03",[1922,1871,1923],"Immunotoxicity","Inert Gas Narcosis",[1901,1925],"Low dose propofol, fentanyl and sevoflurane",{"intervention":1925,"totalTrials":55,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1929,"activeCount":59},[],{"trials":1931,"activeCount":59},[],{"trials":1933,"activeCount":59},[],{"trials":1935,"activeCount":59},[],{"trials":1937,"activeCount":59},[],{"trials":1939,"activeCount":59},[1940],{"nctId":1916,"briefTitle":1917,"status":223,"phases":1941,"primaryCompletion":1919,"completion":459,"start":1920,"enrollment":277,"conditions":1942,"interventions":1943},[52],[1922,1871,1923],[1901,1925],{"intervention":1945,"totalTrials":55,"cells":1946},"Deep anesthesia",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1948,"activeCount":59},[],{"trials":1950,"activeCount":59},[],{"trials":1952,"activeCount":59},[],{"trials":1954,"activeCount":59},[],{"trials":1956,"activeCount":59},[],{"trials":1958,"activeCount":59},[1959],{"nctId":1960,"briefTitle":1961,"status":223,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":1591,"conditions":1966,"interventions":1969},"NCT05380778","Depth of Anesthesia and Proteomics",[52],"2014-07-15","2016-10-23","2009-03-01",[1967,1968],"Anesthesia Complication","Immune Suppression",[1945,1970],"Shallow anesthesia",{"intervention":1970,"totalTrials":55,"cells":1972},{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1974,"activeCount":59},[],{"trials":1976,"activeCount":59},[],{"trials":1978,"activeCount":59},[],{"trials":1980,"activeCount":59},[],{"trials":1982,"activeCount":59},[],{"trials":1984,"activeCount":59},[1985],{"nctId":1960,"briefTitle":1961,"status":223,"phases":1986,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":1591,"conditions":1987,"interventions":1988},[52],[1967,1968],[1945,1970],{"intervention":1814,"totalTrials":55,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":1997,"PHASE4":1999,"NA":2001},{"trials":1992,"activeCount":59},[],{"trials":1994,"activeCount":59},[],{"trials":1996,"activeCount":59},[],{"trials":1998,"activeCount":59},[],{"trials":2000,"activeCount":59},[],{"trials":2002,"activeCount":59},[2003],{"nctId":1806,"briefTitle":1807,"status":177,"phases":2004,"primaryCompletion":1809,"completion":1809,"start":1810,"enrollment":1097,"conditions":2005,"interventions":2006},[],[1812],[1791,1814,1815],{"intervention":2008,"totalTrials":55,"cells":2009},"aerosolized iloprost",{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2014,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2011,"activeCount":59},[],{"trials":2013,"activeCount":59},[],{"trials":2015,"activeCount":59},[],{"trials":2017,"activeCount":59},[],{"trials":2019,"activeCount":59},[],{"trials":2021,"activeCount":59},[2022],{"nctId":2023,"briefTitle":2024,"status":223,"phases":2025,"primaryCompletion":800,"completion":800,"start":774,"enrollment":8,"conditions":2026,"interventions":2027},"NCT00235521","Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery",[52],[18],[2008],{"intervention":2029,"totalTrials":55,"cells":2030},"Redifferentiation with retinoid acid",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2032,"activeCount":59},[],{"trials":2034,"activeCount":59},[],{"trials":2036,"activeCount":59},[],{"trials":2038,"activeCount":59},[],{"trials":2040,"activeCount":59},[],{"trials":2042,"activeCount":59},[2043],{"nctId":2044,"briefTitle":2045,"status":223,"phases":2046,"primaryCompletion":2047,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT03363347","BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer",[],"2014-12-31","2008-01-01",25,[2051],"Thyroid Cancer",[2029],{"intervention":2054,"totalTrials":55,"cells":2055},"Simvastatin 80 mg",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2057,"activeCount":59},[],{"trials":2059,"activeCount":59},[],{"trials":2061,"activeCount":59},[],{"trials":2063,"activeCount":59},[],{"trials":2065,"activeCount":59},[],{"trials":2067,"activeCount":59},[2068],{"nctId":2069,"briefTitle":2070,"status":223,"phases":2071,"primaryCompletion":1566,"completion":762,"start":1329,"enrollment":2072,"conditions":2073,"interventions":2075},"NCT01424891","Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe",[52],31,[184,2074],"Inflammation",[2054,2076],"Sim10\u002FEze10",{"intervention":2076,"totalTrials":55,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2089},{"trials":2080,"activeCount":59},[],{"trials":2082,"activeCount":59},[],{"trials":2084,"activeCount":59},[],{"trials":2086,"activeCount":59},[],{"trials":2088,"activeCount":59},[],{"trials":2090,"activeCount":59},[2091],{"nctId":2069,"briefTitle":2070,"status":223,"phases":2092,"primaryCompletion":1566,"completion":762,"start":1329,"enrollment":2072,"conditions":2093,"interventions":2094},[52],[184,2074],[2054,2076],{"intervention":2096,"totalTrials":55,"cells":2097},"Pergolide",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2099,"activeCount":59},[],{"trials":2101,"activeCount":59},[],{"trials":2103,"activeCount":59},[],{"trials":2105,"activeCount":59},[],{"trials":2107,"activeCount":59},[],{"trials":2109,"activeCount":59},[2110],{"nctId":2111,"briefTitle":2112,"status":223,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":353,"enrollment":2115,"conditions":2116,"interventions":2118},"NCT01066403","Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia",[52],"2008-03",28,[2117],"Schizophrenia",[2096]]